Multivariate meta-analysis of controlled drug studies for obsessive-compulsive disorder

被引:130
作者
Ackerman, DL
Greenland, S
机构
[1] Univ Calif Los Angeles, Sch Publ Hlth, Dept Epidemiol, Los Angeles, CA 90095 USA
[2] Univ Calif Los Angeles, Coll Letters & Sci, Dept Stat, Los Angeles, CA 90095 USA
关键词
D O I
10.1097/00004714-200206000-00012
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Meta-analytic reviews of placebo-controlled studies for obsessive-compulsive disorder have found that clomipramine is more effective than drugs with more selective actions on serotonin reuptake, whereas in most direct comparisons, clomipramine's superiority has been less obvious. The authors used metaregression to identify sources of heterogeneity in placebo-controlled trials of clomipramine, fluvoxamine, sertraline, and paroxetine. They evaluated such patient characteristics as age, gender, age of obsessive-compulsive disorder (OCD) onset, and baseline severity of OCD and depression, and such study characteristics as exclusion or inclusion criteria, length of single-blind prerandomization period, length of trial, number of subjects, and publication year. We found considerable heterogeneity across studies that was associated, in part, with publication year, length of single-blind prerandomization period, length of trial, and severity of patients' OCD. The apparent superiority of clomipramine persisted after controlling for these factors. The authors also confirmed previous reports that placebo response is higher in more recent studies. Meta-analyses can help characterize responders and nonresponders. The authors urge investigators to provide summaries of patient characteristics, especially baseline severity, age at onset, and duration of OCD, by patients' response.
引用
收藏
页码:309 / 317
页数:11
相关论文
共 41 条
[1]   Effectiveness of psychological and pharmacological treatments for obsessive-compulsive disorder: A quantitative review [J].
Abramowitz, JS .
JOURNAL OF CONSULTING AND CLINICAL PSYCHOLOGY, 1997, 65 (01) :44-52
[2]   Side effects as predictors of drug response in obsessive-compulsive disorder [J].
Ackerman, DL ;
Greenland, S ;
Bystritsky, A .
JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY, 1999, 19 (05) :459-465
[3]   Relationship between early side effects and therapeutic effects of clomipramine therapy in obsessive-compulsive disorder [J].
Ackerman, DL ;
Greenland, S ;
Bystritsky, A ;
Katz, RJ .
JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY, 1996, 16 (04) :324-328
[4]  
ACKERMAN DL, 1994, J CLIN PSYCHOPHARM, V14, P247
[5]   Clinical characteristics of response to fluoxetine treatment of obsessive-compulsive disorder [J].
Ackerman, DL ;
Greenland, S ;
Bystritsky, A .
JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY, 1998, 18 (03) :185-192
[6]  
[Anonymous], 1992, Annals of Clinical Psychiatry
[7]  
CHOUINARD G, 1990, PSYCHOPHARMACOL BULL, V26, P279
[8]   CLOMIPRAMINE, FLUOXETINE, AND BEHAVIOR-THERAPY IN THE TREATMENT OF OBSESSIVE-COMPULSIVE DISORDER - A METAANALYSIS [J].
COX, BJ ;
SWINSON, RP ;
MORRISON, B ;
LEE, PS .
JOURNAL OF BEHAVIOR THERAPY AND EXPERIMENTAL PSYCHIATRY, 1993, 24 (02) :149-153
[9]  
DEVEAUGHGEISS J, 1991, ARCH GEN PSYCHIAT, V48, P730
[10]  
FREEMAN CPL, 1994, J CLIN PSYCHIAT, V55, P301